nach oben

Rheumatology International

Erschienen in:

01.11.2015 | Review Article - Review Health Services

Polymyalgia rheumatica: strategies for efficient practice and quality assurance

verfasst von: Michael Schirmer, Christian Dejaco, Bhaskar Dasgupta, Eric L. Matteson

Erschienen in: Rheumatology International | Ausgabe 11/2015

Einloggen, um Zugang zu erhalten

Abstract

Polymyalgia rheumatica (PMR) is the most common inflammatory rheumatic disease in persons over the age of 50 years. There are many diseases which mimic PMR, for which reason a careful diagnostic approach is required. While it is thought to be exquisitely responsive to glucocorticosteroid therapy, many patients respond incompletely and/or develop serious side effects over the protracted disease course. Improved methods for classification and disease assessment together with standardized treatment approaches and outcome assessments can serve to improve the care of patients with this disease.

Lawrence RC, Felson DT, Helmick CG, Arnold LM, Choi H, National Deyo RA, Workgroup Arthritis Data et al (2008) Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II. Arthritis Rheum 58(1):26–35PubMedCentralCrossRefPubMed

Doran MF, Crowson CS, O’Fallon WM, Hunder GG, Gabriel SE (2002) Trends in the incidence of polymyalgia rheumatica over a 30 year period in Olmsted County, Minnesota, USA. J Rheumatol 29:1694–1697PubMed

Weyand CM, Fulbright JW, Evans JM, Hunder GG, Goronzy JJ (1999) Corticosteroid requirements in polymyalgia rheumatica. Arch Int Med 159(6):577–584CrossRef

Matteson EL, Maradit-Kremers H, Cimmino MA, Schmidt WA, Schirmer M, Salvarani C et al (2012) Patient reported outcomes in polymyalgia rheumatica. J Rheumatol 39(4):795–803CrossRefPubMed

Hutchings A, Hollywood J, Lamping DL, Pease CT, Chakravarty K, Silverman B et al (2007) Clinical outcomes, quality of life, and diagnostic uncertainty in the first year of polymyalgia rheumatica. Arthritis Rheum 57(5):803–809CrossRefPubMed

Dasgupta B, Cimmino MA, Maradit-Kremers H, Schmidt WA, Schirmer M, Salvarani C et al (2012) European League Against Rheumatism/American College of Rheumatology provisional classification criteria for polymyalgia rheumatica. Ann Rheum Dis 71:484–492PubMedCentralCrossRefPubMed

Maradit-Kremers H, Dasgupta B, Matteson EL (2009) Polymyalgia rheumatica. In: Preedy VR, Watson RR (eds) Handbook of disease burdens and quality of life measures. Springer, Berlin, pp 3996–4012

BSR and BHPR Standards, Guidelines and Audit Working Group, Dasgupta B, Borg FA, Hassan N, Barraclough K, Bourke B, Fulcher J et al (2010) BSR and BHPR guidelines for the management of polymyalgia rheumatica. Rheumatology (Oxford) 49(1):186–190CrossRef

Dasgupta B, Matteson EL, Maradit-Kremers H (2007) Management guidelines and outcome measures in polymyalgia rheumatica (PMR). Clin Exp Rheumatol 25(suppl 47):S130–S136

10.

ACR/EULAR PMR Guidelines Development Group, Dejaco C, Singh Y, Perel P, Hutchings A, Matteson EL, Dasgupta B (2014) Current evidence for therapeutic interventions in polymyalgia rheumatica (PMR): a systematic literature review informing the ACR/EULAR recommendations for the management of PMR. Ann Rheum Dis 73(suppl2):552

11.

Salvarani C, Cantini F, Boiardi L, Hunder GG (2002) Polymyalgia rheumatica and giant-cell arteritis. N Engl J Med 347(4):261–271CrossRefPubMed

12.

Weyand CM, Goronzy JJ (2014) Clinical practice. Giant-cell arteritis and polymyalgia rheumatica. N Engl J Med 371(1):50–57PubMedCentralCrossRefPubMed

13.

Gonzalez-Gay MA, Garcia-Porrua C, Salvarani C, Olivieri I, Hunder GG (2000) The spectrum of conditions mimicking polymyalgia rheumatica in Northwestern Spain. J Rheumatol 27:2179–2184PubMed

14.

Macchioni P, Catanoso MG, Pipitone N, Boiardi L, Salvarani C (2009) Longitudinal examination with shoulder ultrasound of patients with polymyalgia rheumatica. Rheumatology (Oxford) 48(12):1566–1569CrossRef

15.

De Miguel E, Roxo A, Castillo C, Peiteado D, Villalba A, Martin-Mola E (2012) The utility and sensitivity of colour Doppler ultrasound in monitoring changes in giant cell arteritis. Clin Exp Rheumatol 30(1 Suppl 70):S34–S38PubMed

16.

Schmidt WA (2013) Polymyalgia rheumatica. Z Rheumatol 72(1):59–65CrossRefPubMed

17.

Dasgupta B, Dolan AL, Panayi GS, Fernandes L (1998) An initially double-blind controlled 96 week trial of depot methylprednisolone against oral prednisolone in the treatment of polymyalgia rheumatica. Br J Rheumatol 37(2):189–195CrossRefPubMed

18.

Kyle V, Hazleman BL (1993) The clinical and laboratory course of polymyalgia rheumatica/giant cell arteritis after the first 2 months of treatment. Ann Rheum Dis 52(12):847–850PubMedCentralCrossRefPubMed

19.

Hernández-Rodríguez J, Cid MC, López-Soto A, Espigol-Frigolé G, Bosch X (2009) Treatment of polymyalgia rheumatica: a systematic review. Arch Intern Med 169(20):1839–1850CrossRefPubMed

20.

Maradit Kremers HM, Reinalda MS, Crowson CS, Zinsmeister AR, Hunder GG, Gabriel SE (2005) Relapse in a population based cohort of patients with polymyalgia rheumatica. J Rheumatol 32(1):65–73

21.

Mackie SL, Hensor EM, Haugeberg G, Bhakta B, Pease CT (2010) Can the prognosis of polymyalgia rheumatica be predicted at disease onset? Results from a 5-year prospective study. Rheumatology (Oxford) 49:716–722CrossRef

22.

Myklebust G, Gran JT (2001) Prednisolone maintenance dose in relation to starting dose in the treatment of polymyalgia rheumatica and temporal arteritis. A prospective 2-year study in 273 patients. Scand J Rheumatol 30:260–267CrossRefPubMed

23.

Maradit Kremers H, Reinalda MS, Crowson CS, Zinsmeister AR, Hunder GG, Gabriel SE (2005) Use of physician services in a population-based cohort of patients with polymyalgia rheumatica over the course of their disease. Arthr Care Res 53(3):395–403CrossRef

24.

Kremers HM, Reinalda MS, Crowson CS, Zinsmeister AR, Hunder GG, Gabriel SE (2005) Direct medical costs of polymyalgia rheumatica. Arthritis Rheum 53(4):578–584CrossRefPubMed

25.

Caporali R, Cimmino MA, Ferraccioli G, Gerli R, Klersy C, Salvarani C et al (2004) Prednisone plus methotrexate for polymyalgia rheumatica: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 141(7):493–500CrossRefPubMed

26.

Ferraccioli G, Salaffi F, De Vita S, Casatta L, Bartoli E (1996) Methotrexate in polymyalgia rheumatica: preliminary results of an open, randomized study. J Rheumatol 23(4):624–628PubMed

27.

van der Veen MJ, Dinant HJ, van Booma-Frankfort C, van Albada-Kuipers GA, Bijlsma JW (1996) Can methotrexate be used as a steroid sparing agent in the treatment of polymyalgia rheumatica and giant cell arteritis? Ann Rheum Dis 55(4):218–223PubMedCentralCrossRefPubMed

28.

Gabriel SE, Sunku J, Salvarani C, O’Fallon WM, Hunder GG (1997) Adverse outcomes of anti-inflammatory therapy among patients with polymyalgia rheumatica. Arthritis Rheum 40(10):1873–1878CrossRefPubMed

29.

Cleuziou C, Binard A, De Bandt M, Berthelot JM, Saraux A (2012) Contribution of the polymyalgia rheumatica activity score to glucocorticoid dosage adjustment in everyday practice. J Rheumatol 39(2):310–313CrossRefPubMed

30.

Macchioni P, Boiardi L, Catanoso M, Pazzola G, Salvarani C (2014) Performance of the new 2012 EULAR/ACR classification criteria for polymyalgia rheumatica: comparison with the previous criteria in a single-centre study. Ann Rheum Dis 73(6):1190–1193CrossRefPubMed

31.

Mackie SL, Arat S, da Silva J, Duarte C, Halliday S, Hughes R et al (2014) Polymyalgia Rheumatica (PMR) Special Interest Group at OMERACT 11: outcomes of importance for patients with PMR. J Rheumatol 41(4):819–823CrossRefPubMed

32.

Leeb BF, Rintelen B, Sautner J, Fassl C, Bird HA (2007) The polymyalgia rheumatica activity score in daily use: proposal for a definition of remission. Arthritis Rheum 57(5):810–815CrossRefPubMed

33.

Inflammatory Joint Disease Working Group of the French Society for Rheumatology, Binard A, de Bandt M, Berthelot JM, Saraux A (2008) Performance of the polymyalgia rheumatica activity score for diagnosing disease flares. Arthritis Rheum 59(2):263–269CrossRef

34.

Bahlas S, Ramos-Remus C, Davis P (2000) Utilisation and costs of investigations, and accuracy of diagnosis of polymyalgia rheumatica by family physicians. Clin Exp Rheumatol 19:278–280CrossRef

35.

Dejaco C, Duftner C, Cimmino MA, Dasgupta B, Salvarani C, Crowson CS et al (2011) Definition of remission and relapse in polymyalgia rheumatica—data from a literature search compared to a Delphi based expert consensus. Ann Rheum Dis 70(3):447–453PubMedCentralCrossRefPubMed

36.

Kalke S, Mukerjee D, Dasgupta B (2000) A study of the health assessment questionnaire to evaluate functional status in polymyalgia rheumatica. Rheumatology (Oxford) 39(8):883–885CrossRef

37.

Gran JT, Myklebust G, Wilsgaard T, Jacobsen BK (2001) Survival in polymyalgia rheumatica and temporal arteritis: a study of 398 cases and matched population controls. Rheumatology (Oxford) 40(11):1238–1242CrossRefPubMed

Titel: Polymyalgia rheumatica: strategies for efficient practice and quality assurance
verfasst von: Michael Schirmer
Christian Dejaco
Bhaskar Dasgupta
Eric L. Matteson
Publikationsdatum: 01.11.2015
Verlag: Springer Berlin Heidelberg
Erschienen in: Rheumatology International / Ausgabe 11/2015
Print ISSN: 0172-8172
Elektronische ISSN: 1437-160X
DOI: https://doi.org/10.1007/s00296-015-3297-y

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

25.04.2024 | Hypotonie | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Polymyalgia rheumatica: strategies for efficient practice and quality assurance

Abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Update Innere Medizin

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 11/2015

Left ventricular intracardiac thrombus in a patient with Behçet disease successfully treated with immunosuppressive agents without anticoagulation: a case report and review of the literature

MRI-detected bone marrow changes within 3 weeks after initiation of high-dose corticosteroid therapy: a possible change preceding the subsequent appearance of low-intensity band in femoral head osteonecrosis

Rheumatoid arthritis patients fulfilling Korean National Health Insurance reimbursement guidelines for anti-tumor necrosis factor-α treatment and comparison to other guidelines

Patient and clinical characteristics associated with gout flares in an integrated healthcare system

Synthetic disease-modifying antirheumatic drug prescribing variability in rheumatoid arthritis: a multilevel analysis of a cross-sectional national study

Direct medical costs and their predictors in South Korean patients with systemic lupus erythematosus

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Update Innere Medizin